Idenix Pharma (IDIX) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-98.58M
Depreciation and amortization
Share-based compensation expense	3.08M
Revenue adjustment for contingently issuable shares	29.45M
Other	5K
Receivables from related party
Other assets	-759K
Accounts payable	-353K
Accrued expenses and other current liabilities	9.56M
Deferred revenue
Deferred revenue, related party
Other liabilities	-34K
Net cash used in operating activities
Purchases of property and equipment	-336K
Sales of marketable security
Net cash provided by (used in) investing activities
Proceeds from exercise of common stock options	6.47M
Proceeds from issuance of common stock to related party
Proceeds from issuance of common stock, net of offering costs	106.59M
Net cash provided by financing activities
Effect of changes in exchange rates on cash and cash equivalents	-39K
Net increase in cash and cash equivalents	55.61M
Cash and cash equivalents at beginning of period	122.01M
Cash and cash equivalents at end of period	177.61M
Change in value of shares of common stock contingently issuable or issued to related party

Entities mentioned with IDIX

View All Entities